Institutional Ownership
Acrivon Therapeutics Inc
CUSIP 004890109COMMON STOCKACRVQ1 2026
13D / 13G Filings
24
Schedule 13D/13G on record
Beneficial Filers
9
Distinct reporting persons
Largest Stake
27.1%
Max % of class reported
Institutional Holders
41
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
24 filings · latest Nov 21, 2025
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Nov 21, 2025 | Citadel Advisors LLC | 13G | 5.5% | 1.72M | SEC |
| 2 | Nov 14, 2025 | Citadel Advisors LLC | 13G/A | 4.9% | 1.54M | SEC |
| 3 | Aug 13, 2025 | Sands Capital Life Sciences Pulse Fund II, L.P. | 13G/A | 6.8% | 2.12M | SEC |
| 4 | Jun 4, 2025 | Perceptive Advisors LLC | 13G/A | — | — | SEC |
| 5 | May 15, 2025 | Citadel Advisors LLC | 13G/A | 6.0% | 1.90M | SEC |
| 6 | May 1, 2025 | Perceptive Advisors LLC | 13G/A | 9.9% | 3.10M | SEC |
| 7 | Jul 10, 2024 | Chione Ltd | 13G/A | 12.5% | 3.85M | SEC |
| 8 | Jul 10, 2024 | Chione Ltd | 13G/A | 17.3% | 3.85M | SEC |
| 9 | Apr 15, 2024 | Perceptive Advisors LLC | 13G/A | 17.4% | 5.36M | SEC |
| 10 | Apr 11, 2024 | Ra Capital Management, L.P. | 13D/A | 27.1% | 8.36M | SEC |
14 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Acrivon Therapeutics Inc.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Ra Capital Management, L.P. | 8.34M | $11.59M |
| 2 | Sands Capital Alternatives, LLC | 2.12M | $2.95M |
| 3 | Wellington Management Group LLP | 888.1K | $1.23M |
| 4 | Renaissance Technologies LLC | 758.4K | $1.05M |
| 5 | Marshall Wace, LLP | 560.4K | $779.0K |
| 6 | Two Sigma Investments, LP | 389.4K | $541.3K |
| 7 | Jane Street Group, LLC | 239.7K | $333.2K |
| 8 | Geode Capital Management, LLC | 236.4K | $328.7K |
| 9 | Blackrock, Inc. | 208.9K | $290.4K |
| 10 | Bridgeway Capital Management, LLC | 158.9K | $220.9K |